DE69426292D1 - Stabilisierung von mit organischen lösungsmittel behandelten polypeptiden mit einem hilfsstoff - Google Patents

Stabilisierung von mit organischen lösungsmittel behandelten polypeptiden mit einem hilfsstoff

Info

Publication number
DE69426292D1
DE69426292D1 DE69426292T DE69426292T DE69426292D1 DE 69426292 D1 DE69426292 D1 DE 69426292D1 DE 69426292 T DE69426292 T DE 69426292T DE 69426292 T DE69426292 T DE 69426292T DE 69426292 D1 DE69426292 D1 DE 69426292D1
Authority
DE
Germany
Prior art keywords
pct
stabilization
organic solvent
auxiliary substance
polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69426292T
Other languages
English (en)
Other versions
DE69426292T2 (de
Inventor
Jeffrey L Cleland
Andrew J S Jones
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of DE69426292D1 publication Critical patent/DE69426292D1/de
Application granted granted Critical
Publication of DE69426292T2 publication Critical patent/DE69426292T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
DE69426292T 1993-02-23 1994-02-17 Stabilisierung von mit organischen lösungsmittel behandelten polypeptiden mit einem hilfsstoff Expired - Lifetime DE69426292T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2142193A 1993-02-23 1993-02-23
PCT/US1994/001666 WO1994019020A1 (en) 1993-02-23 1994-02-17 Excipient stabilization of polypeptides treated with organic solvents

Publications (2)

Publication Number Publication Date
DE69426292D1 true DE69426292D1 (de) 2000-12-21
DE69426292T2 DE69426292T2 (de) 2001-05-17

Family

ID=21804127

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69426292T Expired - Lifetime DE69426292T2 (de) 1993-02-23 1994-02-17 Stabilisierung von mit organischen lösungsmittel behandelten polypeptiden mit einem hilfsstoff

Country Status (17)

Country Link
US (3) US5589167A (de)
EP (1) EP0686045B1 (de)
JP (1) JP3698721B2 (de)
CN (1) CN1108823C (de)
AT (1) ATE197550T1 (de)
AU (1) AU685784B2 (de)
CZ (1) CZ296649B6 (de)
DE (1) DE69426292T2 (de)
DK (1) DK0686045T3 (de)
ES (1) ES2153418T3 (de)
GR (1) GR3035383T3 (de)
IL (1) IL108713A (de)
NZ (1) NZ262634A (de)
PT (1) PT686045E (de)
RU (1) RU2143889C1 (de)
WO (1) WO1994019020A1 (de)
ZA (1) ZA941239B (de)

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6586006B2 (en) 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
WO1996008979A1 (en) 1994-09-22 1996-03-28 Quadrant Holdings Cambridge Limited Compositions for use in rehydration and nutrition during athletic exercise and methods of making same
US6964771B1 (en) 1995-06-07 2005-11-15 Elan Drug Delivery Limited Method for stably incorporating substances within dry, foamed glass matrices
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
JP2014148555A (ja) * 1995-07-27 2014-08-21 Genentech Inc タンパク質の処方
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
WO1997004801A1 (en) * 1995-07-27 1997-02-13 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US5762961A (en) * 1996-02-09 1998-06-09 Quadrant Holdings Cambridge Ltd. Rapidly soluble oral solid dosage forms, methods of making same, and compositions thereof
US5958455A (en) * 1996-02-09 1999-09-28 Quadrant Holdings Cambridge Ltd Oral solid dosage forms, methods of making same and compositions thereof
AUPN801296A0 (en) * 1996-02-12 1996-03-07 Csl Limited Stabilised growth hormone formulation and method of preparation thereof
EP0889722B1 (de) 1996-03-28 2002-11-20 Takeda Chemical Industries, Ltd. Zubereitung mit verzögerter freisetzung und deren herstellung
US6632648B1 (en) * 1996-05-14 2003-10-14 Elan Drug Delivery Limited Methods of terminal sterilization of fibrinogen
US5916582A (en) * 1996-07-03 1999-06-29 Alza Corporation Aqueous formulations of peptides
IL127769A (en) * 1996-07-03 2006-10-31 Alza Corp Non-aqueous protic preparations of peptides
US5932547A (en) * 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
US5861174A (en) * 1996-07-12 1999-01-19 University Technology Corporation Temperature sensitive gel for sustained delivery of protein drugs
US5981489A (en) * 1996-07-18 1999-11-09 Alza Corporation Non-aqueous protic peptide formulations
US6468782B1 (en) * 1996-12-05 2002-10-22 Quadrant Healthcare (Uk) Limited Methods of preserving prokaryotic cells and compositions obtained thereby
WO1998027980A2 (en) 1996-12-20 1998-07-02 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6991790B1 (en) * 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US6663899B2 (en) * 1997-06-13 2003-12-16 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6113947A (en) * 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
JP2001510151A (ja) 1997-07-18 2001-07-31 インファイムド，インク． 生理活性物質の制御放出のための生分解性マクロマー
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
EP1071465A1 (de) * 1998-03-18 2001-01-31 Ronai, Peter Amorphe gläser zur stabilisierung von empfindlichen produkten
DE69936638T2 (de) * 1998-04-03 2008-05-21 Novartis Vaccines and Diagnostics, Inc., Emeryville IGF-enthaltende injizierbare Formulierungen, enthaltend Succinat als Puffermittel
CN1379681A (zh) * 1998-04-17 2002-11-13 安乔格尼克斯公司 治疗性的血管生成因子及其使用方法
US6284282B1 (en) * 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
US6190701B1 (en) 1999-03-17 2001-02-20 Peter M. Ronai Composition and method for stable injectable liquids
GB9910975D0 (en) * 1999-05-13 1999-07-14 Univ Strathclyde Rapid dehydration of proteins
US6566329B1 (en) * 1999-06-28 2003-05-20 Novo Nordisk A/S Freeze-dried preparation of human growth hormone
US6102896A (en) * 1999-09-08 2000-08-15 Cambridge Biostability Limited Disposable injector device
US7582311B1 (en) 1999-10-15 2009-09-01 Genentech, Inc. Injection vehicle for polymer-based formulations
US7651703B2 (en) * 1999-10-15 2010-01-26 Genentech, Inc. Injection vehicle for polymer-based formulations
WO2001058428A1 (en) * 2000-02-10 2001-08-16 Alkermes Controlled Therapeutics, Inc. Method of preparing a sustained release composition
US6992065B2 (en) 2000-04-19 2006-01-31 Genentech, Inc. Sustained release formulations
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
WO2001085136A2 (en) 2000-05-10 2001-11-15 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US6653062B1 (en) 2000-07-26 2003-11-25 Wisconsin Alumni Research Foundation Preservation and storage medium for biological materials
EP1309312A2 (de) * 2000-08-07 2003-05-14 Inhale Therapeutic Systems, Inc. Inhalierbare sprühgetrocknete pulver aus proteinen die bündel aus 4 helices ausbilden mit minimierter aggregation
US6824822B2 (en) * 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
EP1452171B1 (de) * 2000-10-13 2009-12-02 Cambridge Biostability Limited Pharmazeutische flüssige Suspensionen
KR100587237B1 (ko) * 2000-11-29 2006-06-07 이토햄 가부시키가이샤 분말제제 및 그의 제조방법
US20040022861A1 (en) * 2001-01-30 2004-02-05 Williams Robert O. Process for production of nanoparticles and microparticles by spray freezing into liquid
DE60231862D1 (de) * 2001-02-23 2009-05-20 Genentech Inc Erodierbare polymere zur injektion
US7318931B2 (en) * 2001-06-21 2008-01-15 Genentech, Inc. Sustained release formulation
GB0116074D0 (en) * 2001-06-29 2001-08-22 Univ Strathclyde Nanoparticle structures
GB2391480B (en) 2002-08-05 2007-02-28 Caretek Medical Ltd Drug delivery system
GB2379390B (en) * 2001-09-11 2005-01-26 Caretek Medical Ltd A novel drug delivery technology
US7615234B2 (en) * 2001-09-11 2009-11-10 Glide Pharmaceutical Technologies Limited Drug delivery technology
JP2005514393A (ja) 2001-12-19 2005-05-19 ネクター セラピューティクス アミノグリコシドの肺への供給
WO2003087783A1 (en) * 2002-04-05 2003-10-23 Powerzyme, Inc. Analyte sensor
AU2003230320A1 (en) * 2002-05-09 2003-11-11 Peptron Co., Ltd Sustained release formulation of protein and preparation method thereof
US7045552B2 (en) * 2002-09-27 2006-05-16 Trimeris, Inc. Pharmaceutical composition for improved administration of HIV gp41-derived peptides, and its use in therapy
CN100444848C (zh) * 2002-09-27 2008-12-24 特里梅里斯公司 HIV gp41-衍生肽的改善用药的药物组合物
WO2004035762A2 (en) 2002-10-17 2004-04-29 Alkermes Controlled Therapeutics, Inc. Ii Microencapsulation and sustained release of biologically active polypeptides
ZA200505306B (en) * 2002-12-31 2006-09-27 Altus Pharmaceuticals Inc Complexes of protein crystals and ionic polymers
SG176314A1 (en) * 2002-12-31 2011-12-29 Altus Pharmaceuticals Inc Human growth hormone crystals and methods for preparing them
US20040197413A1 (en) * 2003-04-04 2004-10-07 Genteric, Inc. Spray dry coacervation systems and methods
DE10320609A1 (de) * 2003-05-08 2004-12-02 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Sprühgefriergranulate mit verbesserter Homogenität der Eigenschaftsverteilung und Verfahren zu deren Herstellung
US7090433B2 (en) * 2003-10-07 2006-08-15 Steve Searby Underground cable laying apparatus
US20050095320A1 (en) * 2003-10-29 2005-05-05 Richard Botteri [An Isotonic Sports Drink for Female Athletes Fortified with Iron, Calcium and Essential Vitamins for Use in Rehydration and Nutrition During Execise and Competition]
US20050100636A1 (en) * 2003-11-10 2005-05-12 Megan Botteri [A Low-Calorie Sports Drink For Physically Active Women That is Fortified with Iron, Calcium and Essential Vitamins for Use in Rehydration and Replacing Electrolytes Lost During Periods of Physical Activity]
BRPI0418304A (pt) * 2004-01-07 2007-05-02 Trimeris Inc peptìdeo sintético, uso do mesmo, composição farmacêutica, seqüência de nucleotìdeos, e, métodos para inibição da transmissão de hiv para uma célula, para inibição da fusão de hiv, e para tratamento de um indivìduo infectado com hiv
US7456254B2 (en) * 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
WO2005110425A1 (en) 2004-04-15 2005-11-24 Alkermes, Inc. Polymer-based sustained release device
JP2007277094A (ja) * 2004-06-29 2007-10-25 Chemo Sero Therapeut Res Inst 改変ダニ主要アレルゲン含有医薬組成物
US7133638B2 (en) * 2004-11-18 2006-11-07 Xerox Corporation Scanning method and an image-processing device including the same
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
GB2422784A (en) * 2005-02-07 2006-08-09 Caretek Medical Ltd Disposable assembly comprising a needle or stylet
WO2006096488A2 (en) * 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc Composition comprising human igg2 antibody and chelating agent
CN100342909C (zh) * 2005-05-11 2007-10-17 北京双鹭药业股份有限公司 一种胸腺素α1的水溶液制剂、其制备方法及应用
CN100337684C (zh) * 2005-05-11 2007-09-19 北京双鹭药业股份有限公司 一种胸腺五肽的水溶液制剂、其制备方法及应用
CN100336557C (zh) * 2005-05-11 2007-09-12 北京双鹭药业股份有限公司 一种生长抑素的水溶液制剂、其制备方法及应用
GB0517688D0 (en) * 2005-08-31 2005-10-05 Cambridge Biostability Ltd Improvements in the stabilisation of biological materials
CN101822820A (zh) * 2005-12-20 2010-09-08 布里斯托尔—迈尔斯斯奎布公司 稳定蛋白质制剂
US9309316B2 (en) * 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
AU2006330833A1 (en) * 2005-12-23 2007-07-05 Altus Pharmaceuticals Inc. Compositions comprising polycation-complexed protein crystals and methods of treatment using them
US7456251B2 (en) 2006-02-02 2008-11-25 Trimeris, Inc. HIV fusion inhibitor peptides with improved biological properties
BRPI0621510A2 (pt) * 2006-03-13 2011-12-13 Becker & Co Naturinwerk pó de colágeno seco, uso e processo para preparação do mesmo, composição a base de colágeno termoplástica homogênea, uso e processo para obter a mesma, artigo em formato sólido e processo para fabricar o mesmo
PL2359808T3 (pl) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotyczne systemy dostawcze i zespoły tłokowe
US20100028451A1 (en) 2006-09-26 2010-02-04 Trustees Of Tufts College Silk microspheres for encapsulation and controlled release
US8946200B2 (en) * 2006-11-02 2015-02-03 Southwest Research Institute Pharmaceutically active nanosuspensions
AU2007234612B2 (en) 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
JP2010513309A (ja) * 2006-12-18 2010-04-30 アルタス ファーマシューティカルズ インコーポレイテッド ヒト成長ホルモン製剤
ATE516814T1 (de) * 2007-02-02 2011-08-15 Bristol Myers Squibb Co 10fn3 domain zur behandlung von krankheiten begleitet von unerwünschter angiogenese
AU2008214359B2 (en) 2007-02-05 2014-01-16 Apellis Pharmaceuticals, Inc. Local complement inhibition for treatment of complement-mediated disorders
JP2010523564A (ja) * 2007-04-03 2010-07-15 トリメリス，インコーポレーテッド 抗ウイルス性ペプチド治療薬の送達のための新規製剤
MX2009011123A (es) 2007-04-23 2009-11-02 Intarcia Therapeutics Inc Formulaciones de suspensiones de peptidos insulinotropicos y sus usos.
EP2497462A1 (de) * 2007-06-01 2012-09-12 Novo Nordisk A/S Stabile nichtwässrige pharmazeutische Zusammensetzungen
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
WO2009020744A1 (en) 2007-08-07 2009-02-12 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations comprising gdf-5 in aqueous acidic solution
JP2010540528A (ja) * 2007-09-25 2010-12-24 トリメリス，インコーポレーテッド 治療的抗ウイルス性ペプチドの新規合成方法
EP2240155B1 (de) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Vorrichtungen, formulierungen und verfahren zur freisetzung mehrerer wirkstoffe
US8404850B2 (en) * 2008-03-13 2013-03-26 Southwest Research Institute Bis-quaternary pyridinium-aldoxime salts and treatment of exposure to cholinesterase inhibitors
RU2571857C2 (ru) 2008-03-18 2015-12-20 Ново Нордиск А/С Стабилизированные по отношению к протеазам ацилированные аналоги инсулина
WO2009129101A1 (en) * 2008-04-14 2009-10-22 Advanced Technologies And Regenerative Medicine, Llc Liquid buffered gdf-5 formulations
US8722706B2 (en) * 2008-08-15 2014-05-13 Southwest Research Institute Two phase bioactive formulations of bis-quaternary pyridinium oxime sulfonate salts
US8309134B2 (en) * 2008-10-03 2012-11-13 Southwest Research Institute Modified calcium phosphate nanoparticle formation
UA106606C2 (uk) * 2009-03-16 2014-09-25 Родія Оперейшнс Стабілізована біоцидна композиція
US20120070427A1 (en) 2009-06-01 2012-03-22 Trustees Of Tufts College Vortex-induced silk fibroin gelation for encapsulation and delivery
RU2431496C2 (ru) * 2009-09-15 2011-10-20 Общество С Ограниченной Ответственностью "Герофарм" Инъекционная лекарственная форма для лечения острого ишемического инсульта и черепно-мозговой травмы, способ ее изготовления и применение
NZ598686A (en) 2009-09-28 2014-05-30 Intarcia Therapeutics Inc Rapid establishment and/or termination of substantial steady-state drug delivery
US9028873B2 (en) * 2010-02-08 2015-05-12 Southwest Research Institute Nanoparticles for drug delivery to the central nervous system
SI3345615T1 (sl) 2010-03-01 2020-03-31 Bayer Healthcare Llc Optimizirana monoklonska protitelesa proti zaviralcu poti tkivnega faktorja (TFPI)
WO2011109691A2 (en) 2010-03-05 2011-09-09 Trustees Of Tufts College Silk-based ionomeric compositions
GB201004072D0 (en) 2010-03-11 2010-04-28 Turzi Antoine Process, tube and device for the preparation of wound healant composition
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
PE20191242A1 (es) 2011-10-25 2019-09-16 Prothena Biosciences Ltd Formulaciones de anticuerpo y metodos
WO2013096835A1 (en) * 2011-12-23 2013-06-27 Abbvie Inc. Stable protein formulations
US9901648B2 (en) 2012-01-27 2018-02-27 The Regents Of The University Of California Stabilization of biomolecules using sugar polymers
MX2014012096A (es) 2012-04-11 2014-11-21 Novo Nordisk As Formulaciones de insulina.
WO2014035798A1 (en) 2012-08-30 2014-03-06 Sanofi Silk lyogels for sustained release of protein therapeutics and methods of making and uses
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
AU2015254307B2 (en) * 2014-04-28 2019-11-07 Eisai R&D Management Co., Ltd. Lyophilized formulation of HGF
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
AU2016270984B2 (en) 2015-06-03 2021-02-25 Intarcia Therapeutics, Inc. Implant placement and removal systems
WO2017104759A1 (ja) * 2015-12-16 2017-06-22 株式会社 資生堂 タブレット型凍結乾燥化粧料
CN109196099B (zh) 2016-03-17 2022-01-11 卫材R&D管理有限公司 用于生产活性肝细胞生长因子(hgf)的方法
CN109310743A (zh) 2016-05-16 2019-02-05 因塔西亚制药公司 胰高血糖素受体选择性多肽及其使用方法
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
CA3031097A1 (en) * 2016-07-18 2018-01-25 Tissuegen, Inc. Methods and compositions for maintaining the conformation and structural integrity of biomolecules
HRP20221324T1 (hr) 2016-12-16 2022-12-23 Novo Nordisk A/S Farmaceutski pripravci koji sadrže inzulin
EP3565580B1 (de) 2017-01-03 2024-03-06 i2o Therapeutics, Inc. Kontinuierlicher verabreichung von exenatid und co-verabreichung von acetaminophen, ethinylestradiol oder levonorgestrel
JP6404405B1 (ja) * 2017-06-14 2018-10-10 株式会社 資生堂 タブレット型凍結乾燥化粧料
US20210145705A1 (en) * 2017-06-19 2021-05-20 Shiseido Company, Ltd. Tablet-type freeze-dried cosmetic
TWI787186B (zh) * 2017-06-19 2022-12-21 日商資生堂股份有限公司 錠型凍結乾燥化妝料
CN108169499A (zh) * 2017-11-30 2018-06-15 成都斯马特科技有限公司 一种基于生化试剂盘进行凝血分析的方法
MY196513A (en) * 2018-09-14 2023-04-18 Cara Therapeutics Inc Oral Formulations of Kappa Opioid Receptor Agonists
US20220088589A1 (en) 2019-01-21 2022-03-24 Eclipse Medcorp, Llc Methods, Systems and Apparatus for Separating Components of a Biological Sample
WO2023150580A2 (en) * 2022-02-01 2023-08-10 Ocular Therapeutix, Inc. A controlled release implant for biologics and corresponding methods of treatment

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3664963A (en) * 1969-10-22 1972-05-23 Balchem Corp Encapsulation process
IT1103817B (it) * 1978-06-27 1985-10-14 Guaber Spa Composizione deodorante granulare per posacenere
DE2916711A1 (de) * 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
EP0193917A3 (de) * 1985-03-06 1987-09-23 American Cyanamid Company Wasserdispersible und wasserlösliche Polymerzusammensetzungen für parenterale Anwendung
US4891319A (en) * 1985-07-09 1990-01-02 Quadrant Bioresources Limited Protection of proteins and the like
GB8604983D0 (en) * 1986-02-28 1986-04-09 Biocompatibles Ltd Protein preservation
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
JP2526589B2 (ja) * 1986-08-08 1996-08-21 武田薬品工業株式会社 ペプチド含有マイクロカプセルおよびその製造法
US5312745A (en) * 1987-06-18 1994-05-17 Chromogenix Ab Determination of components active in proteolysis
ATE82506T1 (de) * 1987-08-21 1992-12-15 Imcera Group Inc Stabilisierung von wachstumshormonen.
WO1989003671A1 (en) * 1987-10-29 1989-05-05 Dainippon Pharmaceutical Co., Ltd. Sustained-release preparation
GB8801338D0 (en) * 1988-01-21 1988-02-17 Quadrant Bioresources Ltd Preservation of viruses
JP2670680B2 (ja) * 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
AT392079B (de) * 1988-03-11 1991-01-25 Voest Alpine Ind Anlagen Verfahren zum druckvergasen von kohle fuer den betrieb eines kraftwerkes
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
US5039540A (en) * 1989-08-14 1991-08-13 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5032405A (en) * 1989-09-27 1991-07-16 Warner-Lambert Company Oral pharmaceutical composition for acid sensitive proteinaceous agents
US5312705A (en) * 1990-07-27 1994-05-17 Matsushita Electric Industrial Co., Ltd. Photosensitive materials for electrophotography having a double-layer structure of a charge generation layer and a charge transport layer
AU1442592A (en) * 1991-02-20 1992-09-15 Nova Pharmaceutical Corporation Controlled release microparticulate delivery system for proteins
FR2673843B1 (fr) * 1991-03-14 1995-01-13 Centre Nat Rech Scient Composition pharmaceutique implantable, bioresorbable a base de poly(acide lactique), destinee a mettre en óoeuvre une antibiotherapie interne locale.
EP0724433B1 (de) * 1993-10-22 1998-12-30 Genentech, Inc. Verfahren zur herstellung von mikrospharen mit einer wirbelschichtstufe
JPH09504523A (ja) * 1993-10-22 1997-05-06 ジェネンテク，インコーポレイテッド アジュバントのマイクロカプセル化方法および組成物
WO1995011010A1 (en) * 1993-10-22 1995-04-27 Genentech, Inc. Methods and compositions for microencapsulation of antigens for use as vaccines

Also Published As

Publication number Publication date
AU6241294A (en) 1994-09-14
GR3035383T3 (en) 2001-05-31
EP0686045B1 (de) 2000-11-15
JP3698721B2 (ja) 2005-09-21
ES2153418T3 (es) 2001-03-01
CZ296649B6 (cs) 2006-05-17
CZ212795A3 (en) 1996-02-14
CN1108823C (zh) 2003-05-21
AU685784B2 (en) 1998-01-29
DK0686045T3 (da) 2001-03-05
IL108713A0 (en) 1994-05-30
ZA941239B (en) 1995-08-23
DE69426292T2 (de) 2001-05-17
NZ262634A (en) 1997-02-24
EP0686045A1 (de) 1995-12-13
US5753219A (en) 1998-05-19
ATE197550T1 (de) 2000-12-15
CN1118143A (zh) 1996-03-06
IL108713A (en) 1999-12-22
RU2143889C1 (ru) 2000-01-10
WO1994019020A1 (en) 1994-09-01
US5804557A (en) 1998-09-08
PT686045E (pt) 2001-04-30
JPH08507064A (ja) 1996-07-30
US5589167A (en) 1996-12-31

Similar Documents

Publication Publication Date Title
DE69426292T2 (de) Stabilisierung von mit organischen lösungsmittel behandelten polypeptiden mit einem hilfsstoff
DK0507407T3 (da) Multifunktionelle, i vand dispergerbare tværbindingsmidler
ATE460429T1 (de) Polypeptide enthaltend extrazellulären domäne von il-20ra und/oderr il-20rb
ATE236981T1 (de) Von menschlichen t-zellen immunodominante epiropen des virus der c-hepatitis
ATE162221T1 (de) Herstellung von glukoseoxidase in rekombinanten systemen
MY116146A (en) Stabilizer combination
DE69021263D1 (de) Fibronektinbindungsprotein und dessen Herstellung.
DE69309044T2 (de) Behandlung von asthma
EP0552240A4 (en) New method of treating depression
PT1149910E (pt) Composicao farmaceutica contra os tumores e as infeccoes por papilomavirus
ATE223481T1 (de) Peptid der löslichen form von acetylcholinesterase mit aktivität als calciumkanalmodulator
DE69011531T2 (de) Von faktor vii abgeleitete peptide mit antihämostatischer wirkung.
DE59101819D1 (de) Stabilisierung von organischen Polyisocyanaten.
DE69524971D1 (de) Neue familie von proteaseinhibitoren und andere biologisch aktive substanzen
MX22991A (es) Agente edulcorante derivado del acido l-aspartico o l-glutamico y el procedimiento para su preparacion.
ES2104686T3 (es) Uso de una mezcla de peptidos y aminoacidos en la profilaxis o el tratamiento de la demencia.
DE59109235D1 (de) Peptide des HIV-gag Proteins, ihre Herstellung und Verwendung
MY107451A (en) Cloning and expression of a rhoptry associated protein of p.falciparum
CA2154164A1 (en) Excipient stabilization of polypeptides treated with organic solvents
NO981707L (no) Xylanase, oligonukleotidsekvens som koder for xylanase og anvendelse derav
ATE240398T1 (de) Von kaposi-sarkom assoziiertem herpes-virus (kshv,hhv-8) kodiertes polypeptid und dessen verwendung in diagnostik und therapie
ES2129022T3 (es) Proteina condromodulina-i.
SE9402253D0 (sv) Process
NO941562L (no) Anvendelse av brandykinin-anatgonister for fremstilling av et medikament for profylakse eller forbehandling av arteriosklerose
ATE432985T1 (de) Polypeptide mit aktivität der stimulierung von neutrophilen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition